Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.06. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
IMAC HOLDINGS Aktie jetzt für 0€ handeln | |||||
05.06. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.05. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
16.05. | IMAC Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
02.05. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.04. | IMAC Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
03.04. | IMAC Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
31.03. | IMAC Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
25.03. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
07.03. | IMAC Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
28.02. | IMAC Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
19.02. | IMAC Holdings, Inc.: Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay | 1 | GlobeNewswire (USA) | ||
12.02. | IMAC Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
11.02. | IMAC Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
10.02. | IMAC Holdings, Inc.: Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response | 1 | GlobeNewswire (USA) | ||
28.01. | Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings | 740 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59.
Planet... ► Artikel lesen | |
28.01. | Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket | 6 | Benzinga.com | ||
27.01. | IMAC Holdings, Inc.: IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies | 159 | GlobeNewswire (Europe) | Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC Holdings" or the "Company") has launched Ignite Proteomics LLC ("Ignite"), its new subsidiary dedicated to... ► Artikel lesen | |
24.01. | IMAC Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
17.01. | IMAC Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PLUS THERAPEUTICS | 0,318 | -13,37 % | Plus Therapeutics Expects Meaningful Revenue Contributions From CNSide Diagnostics In 2026 | WASHINGTON (dpa-AFX) - Plus Therapeutics, Inc. (PSTV), a clinical-stage pharmaceutical company, expects the revenue contributions of CNSide Diagnostics, LLC to 'become meaningful' in fiscal... ► Artikel lesen | |
LIFEWARD | 0,638 | +9,68 % | Lifeward Ltd.: Administrative Law Judge Determines ReWalk Personal Exoskeleton is "Reasonable and Necessary" for Medicare Beneficiary | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
IMUNON | 0,665 | +4,72 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
ROCKWELL MEDICAL | 0,681 | -0,15 % | ROCKWELL MEDICAL, INC. - 8-K, Current Report | ||
AVINGER | 0,340 | -6,08 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
VIRIDIAN THERAPEUTICS | 12,650 | +3,31 % | Viridian Therapeutics, Inc.\DE - 8-K, Current Report | ||
SINTX TECHNOLOGIES | 3,200 | +1,27 % | Sintx Technologies, Inc. - 8-K, Current Report | ||
AETHLON MEDICAL | 1,430 | -100,00 % | Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update | Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications... ► Artikel lesen | |
NEURONETICS | 2,830 | -0,53 % | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve... ► Artikel lesen | |
STAGEZERO LIFE SCIENCES | 0,028 | -100,00 % | Stagezero Life Sciences Ltd (2): Stagezero, ElevationMD use Aristotle to detect cancer | ||
ARCH THERAPEUTICS | - | - | Arch Therapeutics, Inc. - 8-K, Current Report | ||
HVIVO | 0,117 | +0,86 % | ILiAD Biotechnologies, LLC: ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting | Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough
ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,900 | +0,13 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS | 42,590 | +0,95 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen |